Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04571840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Imaging Using MRI +/- Contrast Enhancement

Study acronym: PRIME
StatusUnknown
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 23, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Primary completion date: Dec 2023 to Dec 1, 2024v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Mar 2024 to Mar 1, 2025
    • Start date: Apr 5, 2022 to Mar 22, 2022
    • Site details revised at 31 of 31 sites
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 28 to 31
    • Start date changed from estimate of Jan 2022 to Apr 5, 2022
    v4
  4. Primary completion date: Aug 2022 to Dec 2023
    • Start date: Nov 2020 to Jan 2022
    • Study sites: 25 to 28
    • Study completion date: Aug 2023 to Mar 2024
    v3
  5. Secondary endpoints revised (7)v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.
Trial Details
NCT Number NCT04571840
Lead Sponsor University College, London
Conditions
(from sponsor)		 Prostate Cancer
Related terms Disease, Prostatic Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov